Drug company claims positive Alzheimer’s results
New preclinical research on a drug in development locally suggests it may protect against some symptoms of Alzheimer’s disease.
The investigational drug, BPN14770, under development by Grand Rapids-based Tetra Therapeutics may protect against memory loss and neuronal atrophy induced by a hallmark protein of Alzheimer’s disease.
In lab mice, the drug was shown to reduce memory impairment, damage to nerve morphology, deficits in synaptic proteins and impaired neurological signaling, according to Tetra.
The research has been published online in the Journal of Pharmacology & Experimental Therapeutics by Su-Ying Cui, Ph.D., and colleagues at the School of Pharmacy and Pharmaceutical Sciences at the University at Buffalo and other Tetra Therapeutics’ collaborators.
Tetra is currently conducting Phase 2 clinical trials of BPN14770 in patients with early Alzheimer’s disease and adults with Fragile X Syndrome. Topline results are expected mid-2020.
"There has been enormous interest in our ongoing Phase 2 trial of BPN14770," said Mark Gurney, Ph.D., chairman and CEO, Tetra Therapeutics. "We are very excited by our colleagues’ findings."
Results of previous Phase 1 studies with BPN14770 in healthy elderly volunteers suggested a cognitive benefit for this investigational drug, Tetra said.